Target Pipelines

Subscribe to
our newsletters!

Showing 21–29 of 29 results

  • April of 2019
    This report provides an overview of CD40 agonistic antibodies, proteins or viral vectors in development for treatment of solid tumors as monotherapy or in combination therapy.
     150.00
  • March of 2019
    This Target Pipeline List provides an overview of biologic and chemical entities on the market or in development for treatment of hyperuricemia associated with gout or tumor lysis
     150.00
  • February of 2019
    This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.
     100.00
  • January of 2019
    This Target Pipeline List provides an overview of biologic and small molecule approaches to raise high density lipoprotein (HDL) for reduction of recurrent cardiovascular events.
     100.00
  • December of 2018
    This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.
     75.00
  • January of 2019
    This Target Pipeline List provides an overview of agonist antibodies and fusion proteins targeting death receptor 4 and/or 5 in development for treatment of cancer.
     100.00
  • January of 2019
    This Target Pipeline list provides an overview of antibody- and cell-based therapeutics targeting DLL3 in development for treatment of DLL3-overexpressing cancers.
     50.00
  • January of 2019
    This Target Pipeline List provides a pipeline overview of tau imaging agents in development for diagnosis of tauopathies and measurement of tau-targeted treatment effects
     50.00
  • January of 2019
    This Target Pipeline List provides a pipeline overview of EP4 receptor antagonists in development for treatment of cancer
     50.00